Haemostatic proteins gene polymorphisms in patients with unusual vein thrombosis and Ph-myeloproliferative disorders [10]

Thrombosis and Haemostasis

Volumn 98, Issue 3, 2007, Pages 702-704

  Randi, Maria L ^a   Lombardi, Anna Maria ^a   Scapin, Margherita ^a   Tezza, Fabiana ^a   Scandellari, Raffaella ^a   Ruzzon, Elisabetta ^a   Duner, Elena ^a   Fabris, Fabrizio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRINOGEN; FIBRINOGEN RECEPTOR; JANUS KINASE 2;

ADULT; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC POLYMORPHISM; HEMOSTASIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LETTER; MALE; MYELOPROLIFERATIVE DISORDER; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RISK FACTOR; SCREENING; THROMBOCYTOSIS; VEIN THROMBOSIS;

ADULT; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; FACTOR XII; FEMALE; FIBRINOGEN; HEMOSTASIS; HUMANS; INTEGRIN BETA3; JANUS KINASE 2; MALE; PHILADELPHIA CHROMOSOME; POLYCYTHEMIA VERA; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC; VENOUS THROMBOSIS;

EID: 34548700610     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-02-0142     Document Type: Letter

References (15)

1. Baxter EJ, Scoff LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myelo-proliferative disorders. Lancet 2005; 365: 1054-1061.
2. Kralovics R, Passamonti F, Buster AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
3. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythemia: clinical association and long-term pronostic relevance. Br J Haematol 2005; 131: 208-213.
4. Vanelli C, Biondi ML, Turri O, et al. SDF1-3′ A gene polymorphism: risk factor for thrombotic events in Philadelphia - negative chronic myeloproliferative disorders. Haematologica 2005; 90 (Suppl 3): 66.
5. Gardellini A, Biondi ML, Turri O, et al. Endothelial nitric oxide syntetase gene polymorphisms (G894T and T786C) in essential thromboythemia. Haematologica 2005; 90 (Suppl 3): 66.
6. Afshar-Karghan V, Lopez JA, Gray LA, et al. Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagul Fibrinolysis 2004; 15: L21-24.
7. Dernninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31: 587-591.
8. Randi NL, Sartori MT, Luzzatto G, et al. Thrombocythosis and recurrent hepatic outflow obstruction (Budd-Chiari syndrome) after successful thrombolysis: case report and literature review. Clin Appl Thromb/Hemost 2002; 8: 369-374.
9. Wang SY, Wei YF, Li JD. The relationship between beta fibrinogen gene-455G/A polymorphisms and Budd-Chiari syndrome. Zhonghua Nei Ke Za Zhi 2004;43:753-755.
10. Tirado I, Soria MJ, Mateo J, et al. Association after linkage analysis indicates that homozygosity for 46 C/T polymorphism in F12 gene is a genetic risk factor for venous thrombosis. Thromb Haemost 2004; 91: 899-904.
11. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999; 36: 9-13.
12. Randi ML, Putti MC, Scapin M, et al. Clonality status and Jak 2 V617F mutation in children with essential thrombocythemia. Blood 2006; 108: 3600-3602.
13. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on Jak2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945-1953.
14. Goerttler PS, Steimle C, Marz E, et al. The Jak2V617F mutation, PRV-1 over-expression and EEC formation define a similar cohort of MPD patients. Blood 2005; 106: 2862-2864.
15. Harrison CN, Gale RE, Machin SJ, et al. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999; 993: 417-424.